Palisade Bio, Inc. (PALI)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Palisade Bio, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Palisade Bio, Inc. (PALI) has returned -25.53% so far this year and 157.05% over the past 12 months. Over the last ten years, PALI has returned -73.04% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Dec 20, 2006, PALI's average daily return is -0.05%, while the average monthly return is -2.37%.

Historically, 41% of months were positive and 59% were negative. The best month was Oct 2025 with a return of +140.8%, while the worst month was Jul 2017 at -73.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.

On a daily basis, PALI closed higher 42% of trading days. The best single day was Dec 5, 2017 with a return of +175.9%, while the worst single day was Aug 9, 2023 at -62.7%.

Palisade Bio, Inc. has an annualized alpha of -19.12%, beta of 0.78, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since December 21, 2006.

• This stock participated in 203.92% of S&P 500 Index downside but only -57.32% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PALI ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Palisade Bio, Inc. (PALI) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Palisade Bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Palisade Bio, Inc. was 100.00%, occurring on Sep 10, 2025. The portfolio has not yet recovered.

The current Palisade Bio, Inc. drawdown is 100.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Palisade Bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Palisade Bio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.